Iannone Robert

EVP R&D sells 7,159 JAZZ shares at $168.26; prior two sales at this ticker both well-timed with negative 90d returns.

Iannone Robert, EVP and Global Head of R&D & CMO, sold 7,159 shares ($1.2M) at $168.26, reducing holdings by 9.0% to 72,628 shares. This sale follows a clear pattern: his two prior sales at JAZZ (both on 2025-03-07) were well-timed at the 90-day mark with negative 90d returns of -21.3% and -22.3%. His cross-ticker track record shows 2 prior sells with a 100.00% well-timed rate and average 90d return of -21.8%, indicating a consistent ability to exit before declines. The current price of $176.08 is now -2.5% from the 52-week high and the stock is up +30.6% over 30 days and +46.1% over 90 days—a notable rally that follows the March sales. The timing signal warrants investor attention given the insider's demonstrated pattern of selling ahead of downturns at this specific ticker.

Jazz Pharma EVP Iannone sold 7,080 shares for $981,297.72 at $138.21–$140.00 on 2025-03-07

Robert Iannone, EVP and Global Head of R&D & CMO at Jazz Pharmaceuticals, executed two separate sales totaling 7,080 shares for $981,297.72 on March 7, 2025, reducing his holdings from 89,104 to 82,024 shares. The sales occurred at prices ($138.21 and $140.00) proximate to the current market price of $138.81 and within the recent 52-week trading range, with the stock up 14.2% over the prior 30 days. The company shows solid fundamentals with $1.054 billion in latest-quarter revenue, $215.055 million net income, and a P/E of 13.85. The disposal reduces Iannone's position by 7.9% but leaves a substantial 82.0K share stake, indicating retained confidence in the company despite the sale.